150 related articles for article (PubMed ID: 2731314)
21. cis-Platinum: subcellular distribution and binding to cytosolic ligands.
Sharma RP; Edwards IR
Biochem Pharmacol; 1983 Sep; 32(18):2665-9. PubMed ID: 6313005
[TBL] [Abstract][Full Text] [Related]
22. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
Verschraagen M; Boven E; Torun E; Hausheer FH; Bast A; van der Vijgh WJ
Biochem Pharmacol; 2004 Aug; 68(3):493-502. PubMed ID: 15242815
[TBL] [Abstract][Full Text] [Related]
23. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma.
Fichtinger-Schepman AM; Vendrik CP; van Dijk-Knijnenburg WC; de Jong WH; van der Minnen AC; Claessen AM; van der Velde-Visser SD; de Groot G; Wubs KL; Steerenberg PA
Cancer Res; 1989 Jun; 49(11):2862-7. PubMed ID: 2720647
[TBL] [Abstract][Full Text] [Related]
24. The interactions of cis-diamminedichloroplatinum with metallothionein and glutathione in rat liver and kidney.
Suzuki CA; Cherian MG
Toxicology; 1990 Nov; 64(2):113-27. PubMed ID: 1977210
[TBL] [Abstract][Full Text] [Related]
25. Quantitative subcellular distribution of platinum in rat tissues following i.v. bolus and i.v. infusion of cisplatin.
Parti R; Wolf W
Cancer Chemother Pharmacol; 1990; 26(3):188-92. PubMed ID: 2357765
[TBL] [Abstract][Full Text] [Related]
26. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration.
Esteban-Fernández D; Verdaguer JM; Ramírez-Camacho R; Palacios MA; Gómez-Gómez MM
J Anal Toxicol; 2008 Mar; 32(2):140-6. PubMed ID: 18334097
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of lactate-dehydrogenase by cisplatin and other platinum-compounds: enzyme leakage of LDH is not a suitable method to measure platinum-compound-induced kidney cell damage in vitro.
Hannemann J; Baumann K
Res Commun Chem Pathol Pharmacol; 1988 Jun; 60(3):371-9. PubMed ID: 3175335
[TBL] [Abstract][Full Text] [Related]
28. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S
Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376
[TBL] [Abstract][Full Text] [Related]
29. The effects of dimercaptosuccinic acid and other chelating agents on the retention of platinum in the rat kidney after treatment with cisplatin.
Planas-Bohne F; Shand E; Taylor DM
Cancer Chemother Pharmacol; 1982; 9(2):120-1. PubMed ID: 6293731
[TBL] [Abstract][Full Text] [Related]
30. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
Esposito M; Vannozzi M; Viale M; Pellecchia C; Civalleri D; Gogioso L
Anticancer Res; 1995; 15(6B):2541-7. PubMed ID: 8669820
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin-induced loss of kidney copper and nephrotoxicity is ameliorated by single dose diethyldithiocarbamate, but not mesna.
DeWoskin RS; Riviere JE
Toxicol Appl Pharmacol; 1992 Feb; 112(2):182-9. PubMed ID: 1311464
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin.
Hanada K; Ninomiya K; Ogata H
J Pharm Pharmacol; 2000 Nov; 52(11):1345-53. PubMed ID: 11186242
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of cisplatin nephrotoxicity.
Weiner MW; Jacobs C
Fed Proc; 1983 Oct; 42(13):2974-8. PubMed ID: 6684595
[TBL] [Abstract][Full Text] [Related]
34. Reduction of cisplatin-induced nephrotoxicity in vivo by selenomethionine: the effect on cisplatin-DNA adducts.
García Sar D; Montes-Bayón M; Blanco González E; Sierra Zapico LM; Sanz-Medel A
Chem Res Toxicol; 2011 Jun; 24(6):896-904. PubMed ID: 21491944
[TBL] [Abstract][Full Text] [Related]
35. Nephrotoxicity of cis-platin comparing young and adult rats.
Jongejan HT; Provoost AP; Wolff ED; Molenaar JC
Pediatr Res; 1986 Jan; 20(1):9-14. PubMed ID: 3945520
[TBL] [Abstract][Full Text] [Related]
36. Protective action of glycine in cisplatin nephrotoxicity.
Heyman SN; Rosen S; Silva P; Spokes K; Egorin MJ; Epstein FH
Kidney Int; 1991 Aug; 40(2):273-9. PubMed ID: 1942775
[TBL] [Abstract][Full Text] [Related]
37. Increase in serum uric acid level associated with cisplatin therapy. Correlation with liver but not kidney platinum concentrations.
Nanji AA; Mikhael NZ; Stewart DJ
Arch Intern Med; 1985 Nov; 145(11):2013-4. PubMed ID: 4062451
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin-induced toxicity is associated with platinum deposition in mouse kidney mitochondria in vivo and with selective inactivation of the alpha-ketoglutarate dehydrogenase complex in LLC-PK1 cells.
Zhang L; Cooper AJ; Krasnikov BF; Xu H; Bubber P; Pinto JT; Gibson GE; Hanigan MH
Biochemistry; 2006 Jul; 45(29):8959-71. PubMed ID: 16846239
[TBL] [Abstract][Full Text] [Related]
39. Stress response inhibits the nephrotoxicity of cisplatin.
Hanigan MH; Deng M; Zhang L; Taylor PT; Lapus MG
Am J Physiol Renal Physiol; 2005 Jan; 288(1):F125-32. PubMed ID: 15353400
[TBL] [Abstract][Full Text] [Related]
40. The effect of methylprednisolone on platinum kinetics and urinary enzyme excretion following intravenous cisplatin in vivo and on the growth inhibition of LLC-PK1 cells by cisplatin in vitro.
Uozumi J; Koikawa Y; Yasumasu T; Tokuda N; Ueda T; Kumazawa J
Res Exp Med (Berl); 1996; 196(4):211-7. PubMed ID: 8903096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
